Showing results (171-180 of 514) with videos related to
Sort By:
Pageof 52
Crohn'S & Colitis 360|February 13, 2023
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative ColitisJaroslaw Kierkus, Marina Pesegova, Maria Klopocka, et al.Crohn'S & Colitis 360|February 13, 2023
Low Skeletal Muscle Index Adjusted for Body Mass Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical ComplicationsMatthew Berger, Akihiro Yamada, Yuga Komaki, et al.Crohn'S & Colitis 360|February 13, 2023
Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in JapanMichio Itabashi, Hiroki Ikeuchi, Hideaki Kimura, et al.Crohn'S & Colitis 360|February 13, 2023
Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic TherapySean Fine, Marc Vecchio, Joao Filipe Goncalves Monteiro, et al.Crohn'S & Colitis 360|February 13, 2023
Early Start of Infliximab in Crohn's Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center CohortFabian Schnitzler, Theresia Seitz, Cornelia Tillack-Schreiber, et al.Crohn'S & Colitis 360|February 13, 2023
Novel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases-LISTEN 1Niels Teich, Hermann Schulze, Jana Knop, et al.Crohn'S & Colitis 360|February 13, 2023
The Reliability of Patient Self-reported Utilization in an Inflammatory Bowel Diseases Learning Health SystemWelmoed K van Deen, Noah Freundlich, Michelle H Kwon, et al.Crohn'S & Colitis 360|February 13, 2023
Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn's DiseaseJose Antonio Quiros, Annie Lintzenich Andrews, Daniel Brinton, et al.Crohn'S & Colitis 360|February 13, 2023
Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational StudyTemara M Hajjat, Maua Mosha, Kaitlin G Whaley, et al.Crohn'S & Colitis 360|February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference BiologicsRemo PanaccionePageof 52